bioRxivCancer BiologyPreprint
DNA replication stress-induced transcriptome of Human Burkitt lymphoma identifies MBD1 as a novel suppressor of BCL6 rearrangements in germinal center derived B-lymphomagenesis
Santosh Kumar GothwaliD, Kyoko Oichai, Jacqueline H. BarlowiD
Abstract
BCL6 is a master transcriptional regulator of germinal center (GC) B cells. BCL6 is frequently translocated at the major translocation cluster (MTC) within intron 1 of the BCL6 locus, a hotspot commonly rearranged in diffuse large B cell lymphomas (DLBCLs). BCL6 amplifications are associated with therapeutic resistance and poor survival outcomes in hematological and solid cancers. However the mechanisms suppressing genome instability at the BCL6-MTC preventing BCL6 rearragements remain unclear. Here, transcriptome analysis and genome-wide mapping of histone H3 lysine 4 trimethylation (H3K4me3) in hydroxyurea (HU)-treated Raji cells (a Burkitts lymphoma model) revealed the induced expression of MBD1, encoding the DNA CpG methylation-binding protein. Functional studies using shRNA silencing and ectopic overexpression demonstrated that MBD1 suppresses BCL6 transcription whose promoter harbours conserved CpG methylation sites, suggesting a DNA methylation-dependent regulation of BCL6 trasncription by MBD1. Conversely, BCL6 repressed MBD1 expression by binding to its promoter. MBD1-depleted Raji cells exhibited increased genomic instability at the BCL6-MTC upon HU treatment, heightened sensitivity to DNA replication inhibitors (HU, gemcitabine, and etoposide), and reduced tumorigenicity in xenograft mouse models. We propose that MBD1 prevents genomic instability at the BCL6-MTC to suppress DLBCL formation. Moreover, MBD1 promotes genomic stability and cell viability during DNA replication stress. MBD1 thus represents a potential therapeutic target for cancers exhibiting resistance to chemotherapies targeting DNA replication. Key PointsO_LIMBD1 suppresses BCL6 expression under the DNA replication stress C_LIO_LIMBD1 suppresses genomic instability at BCL6 translocation hotspots C_LIO_LIMBD1 depletion is associated with reduced tumorigenicity in mouse xenograft and sensitivity to DNA replication inhibitors. C_LI
- organism: human
- assay: bulk RNA-seq
- research focus: chromatin & epigenetic regulation
- research focus: cancer & tumor microenvironment
- approach: statistical model
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Stress Induced Signaling Pathways in Burkitt Lymphoma Play Novel Mechanisms in Fate Determination and Pathogenesis of Germinal Center-Derived B-Lymphomas
Santosh K Gothwal, Jacqueline H Barlow·bioRxiv·Dec 19, 2024
- Lamin B1 Safeguards the B Cell Genome and Shapes Lymphoma Outcome
Filip Filipsky, Katarina B. Chapman, … Tetyana Klymenko·HemaSpherePeer-reviewed·Jun 1, 2026
- The Oncoprotein BCL6 Enables Cancer Cells to Evade Genotoxic Stress
- BET inhibition induces HEXIM1- and RAD51-dependent conflicts between transcription and replication
Akhil Bowry, Ann Liza Piberger, … Eva Petermann·Cell ReportsPeer-reviewed·Nov 1, 2018
- Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition
R. Winkler, A.-S. Mägdefrau, … C. Kosan·OncogenePeer-reviewed·Sep 6, 2022
- BCL6 is a context-dependent mediator of the glioblastoma response to irradiation therapy
A. Tribe, L. Peng, … M. J. McConnell·bioRxiv·May 29, 2023